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Identity 
Other names: MIRN141 
HGNC (Hugo): MIR141 
Location: 12p13.31 
Local order: From telomere to centromere (from 
USCS RefSeq genes): C12orf57 (chromosome 12 
open reading frame 57), PTPN6 (protein tyrosine 
phosphatase non-receptor type 6), MIR200C 
(miRNA-200c), MIR141 (miRNA-141), PHB2 
(prohibitin 2), SCARNA12 (small cajal body specific 
RNA 12), EMG1 (essential for mitotic growth 
nucleolar protein homolog (S. cerevisiae)). 
DNA/RNA 
Note 
miR-141 belongs to the miR-200 family of microRNAs 
(also referred to as miRNAs or miRs). This family is 
composed by five distinct miRNAs, classified into two 
subfamilies according to the sequence homology in 
their seed region (sequence of the miRNA defining its 
target specificity corresponding to nucleotides 2-7). 
The first subfamily includes the miR-141 and miR-
200a and the second one is composed by the miR-200b, 
miR-200c and miR-429. These miRNAs are located 
within two clusters on different genomic loci: miR-
200b, miR-200a and miR-429 are located on 
chromosome 1 in the human genome (chromosome 4 in 
mouse) and miR-141 and miR-200c on human 
chromosome 12 (chromosome 6 in mouse). 
Description 
Genomic location in human genome: chr 12: 7073260-
7073354 (GRCh37/hg19 Assembly). 
Orientation: + strand. 
The mature sequence of MIR-141-3P (most abundant) 
is uaacacugucugguaaagaugg (accession 
MIMAT0000432). 
The sequence of MIR-141-5P (previously called miR-
141*) is caucuuccaguacaguguugga (accession 
MIMAT0004598). 
Transcription 
miRNA genes are generally transcribed by RNA 
polymerase II to generate capped and poly-adenylated 
primary transcripts, called pri-miRNAs. Pri-miRNAs 
are processed in the nucleus by the RNase III enzyme, 
Drosha, generating stem-loop structured RNAs called 
precursor miRNAs, or pre-miRNAs. 




UC (accession MI0000457) and a schematic 
representation of the secondary structure of the stem-
loop is shown above.  
Pre-miRNAs are then exported to the cytoplasm. In the 
cytoplasm, another RNase III enzyme, Dicer, cleaves 
the pre-miRNAs, producing miRNAs duplexes of the 
mature miRNAs (5P and 3P) and then one of the 
strands is loaded into the miRNA-associated RNA-
Induced Silencing Complex, RISC.  
The mature miRNAs are very stable RNA molecules. 
Pseudogene 
Not found (Pseudogene.org Build 68 via GeneCards). 
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A) Sequence of the five members of miR-200 family. The seed sequence is underlined and the two subfamilies are indicated by the 
blue/red bars. B) Schematic representation of the genomic localization of the two clusters containing the miR-200 family members. C) 
Schematic representation of the secondary structure of the pre-miR-141 hairpin. The sequence of the mature miR-141-3P is indicated in 








SNP IDs rs34385807, rs111718468 (both located in 
precursor miRNA but not in mature miRNA). No 




The miR-200 family members are reproducibly found 
up-regulated in ovarian tumors compared to normal 
cells and tissues, in several independent studies 
(Bendoraite et al., 2010; Iorio et al., 2007; Nam et al., 
2008; Wyman et al., 2009; Yang et al., 2008). The 
identification of differentially expressed miRNAs relies 
in part on the choice of normal cells used to compare 
with the tumors. This is an important aspect since 
which cells are at the origin of Epithelial Ovarian 
Cancers (EOC) is still under debate. It has been 
postulated that EOC arise from ovarian surface 
epithelium (OSE) cells. Other theories suggest that t ey 
originate from the fallopian tube or the Mullerian ducts 
(for review, Kurman and Shih, 2010). Among the 
previously cited studies, Iorio et al., 2007 and Nam et 
al., 2008  
used normal ovary as control. The mesenchymal cell 
content in ovarian tissue compared to epithelial cancer 
cells could explain the observed enrichment of miR-
200 members, which are highly expressed in epithelial 
cells. On the contrary, other studies compared ovarian 
tumors to normal human Ovarian Surface Epithelial 
(OSE) cells (Bendoraite et al., 2010; Wyman et al., 
2009; Yang et al., 2008). All these five studies showed 
that miR-200 family miRNAs are highly expressed in 
EOC, suggesting that miR-200 over-expression is not 
only related to the epithelial versus mesenchymal 
content. Taken together, these data strongly suggest 
these miRNA could play a key role in ovarian 
tumorigenesis.  
The prognostic value of miRNAs from the miR-200 
family has been studied by several groups but the 
results are controversial. Two studies suggest that they 
can be associated with poor prognosis (Nam et al., 
2008; Yang et al., 2008), while others indicate the
opposite (Eitan et al., 2009; Hu et al., 2009; Leskelä et 
al., 2011; Marchini et al., 2011; Mateescu et al., 2011).  
Our unpublished analysis, based on a cohort of patients  
treated at the Institut Curie (Mateescu et al., 2011) and  
confirmed in other public available data (Cancer 
Genome Atlas Research Network, 2011) indicate that 
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individual miRNA from the miR-200 family cannot 
robustly predict prognosis.  
Nevertheless, these miRNAs could have an important 
role on clinics as a diagnostic tool. As discussed above, 
miR-200 family members accumulate significantly at 
early phases of ovarian tumorigenesis. Moreover, thse 
miRNAs are detected in the blood of ovarian cancer 
patients, indicating they could be interesting early 
detection biomarkers of EOC (Kan et al., 2012; Taylor 
and Gercel-Taylor, 2008).  
Besides its potential application in diagnostics, the 
level of miR-141 and other miR-200s could also be 
useful for improvement in ovarian cancer patient care.  
The levels of these miRNAs in association with other 
genes could be used for patient stratification and 
therapy choices (for review, Batista et al., 2013). 
Prostate cancer 
Note 
In 2008, the proof of concept for the use of miRNAs in 
blood samples (serum/plasma), as biomarkers of human 
prostate cancers at early stages, has been established 
(Mitchell et al., 2008). Metastatic prostate patients were 
compared to healthy controls and miR-141 can 
distinguish with 100% specificity and 60% sensitivity 
patients with advanced prostate cancers from controls. 
In agreement with these results, another study showed 
that circulating miR-141 is a marker of high-risk 
prostate cancer (as well as miR-375) (Brase et al., 
2011). These miRNAs are also up-regulated in tumor 
specimens and not only detected as circulating 
miRNAs. In another cohort of 21 prostate cancer 
patients, changes in miR-141 levels are correlated with 
variations of other biomarkers of prostate cancer 
disease, such as prostate specific antigen (PSA), 
circulating tumor cells (CTC) and lactate 
dehydrogenase (LDH) (Gonzales et al., 2011).  
Accordingly, in this study, miR-141 can predict tumor 




High miR-141 plasma level is associated with poor 
prognosis in colorectal cancer (CRC) and was proposed 
as a novel biomarker to find distant metastases, to be 
used together with the CEA (Carcinoembryonic 
Antigen) (Cheng et al., 2011). This was validated in 
two independent cohorts from different ethnic 
populations (US and China). Surprisingly, the elevat d 
levels of miR-141 in plasma of stage IV CRC patients 
are not linked to elevated levels of miR-141 in tumor 
tissues at the primary sites. Some hypotheses to explain 
this result are that miR-141 could be elevated only i  
metastases and not in the primary tumor and that the 
circulating miR-141 could be a reflect of differential 
inflammatory response (Cheng et al., 2011).  
In another screening for new miRNAs that could be 
used as biomarkers for the detection of colorectal 
cancer, miR-141 was also detected up-regulated in the 
plasma of CRC patients (Wang et al., 2012b). 
Lung cancer 
Note 
In human lung cancer cell lines, miR-141 levels 
distinguished the cell lines on the basis of their site of 
origin, with higher miR-141 levels in cells from a 
primary lung tumor than in cell lines derived from 
metastatic sites (Gibbons et al., 2009). It has been 
suggested that the metastatic process relies on the 
down-regulation of miR-200s. This hypothesis is 
supported by in vivo data in lung cancer mouse models 
showing that over-expression of miR-200b inhibited 
metastases formation (Gibbons et al., 2009). 
Bladder cancer 
Note 
All members of miR-200 family, including miR-141, 
were up-regulated in a series of nine pairs of bladder 
urothelium carcinoma and matched normal urothelium 
analyzed by deep sequencing (Han et al., 2011). 
Another study revealed that miR-141 is up-regulated in 
bladder tumors compared to normal urothelium, but 
down-regulated in invasive compared to superficial 
tumors (Wiklund et al., 2011). Lower level of miR-141 
was associated with increased DNA methylation and 
histone marks. In this cohort, loss of miR-200c (which 
is transcribed from the same genomic locus) was 
associated with poor outcome.  
It has been described that miR-141 (among others) 
exhibit a lower expression in the urine of patients with 
bladder cancer compared to the control group (Wang et 
al., 2012a). Seventy-five samples were analyzed (24 
controls) as well as nine patients before and after 
surgery. Interestingly, levels of miR-141, after sugery, 
increases back, up to the level of the control group. The 
confirmation of these results in larger cohorts using 
matched age and sex groups is needed. If confirmed, 
these results could indicate the potential role of miR-
141 as a non-invasive biomarker for diagnostics and
monitoring of bladder cancer. 
Kidney cancer 
Note 
Investigation of expression profiles of miRNAs in renal 
cell carcinoma indicated that miR-141 levels are down-
regulated in the clear cell carcinoma (CCC) subtype 
(the most common subtype of renal cell carcinoma) 
compared to normal kidneys (Nakada et al., 2008). 
Although the number of samples analyzed was limited 
(16 CCC samples and 6 controls) the down-regulation 
of miR-141 was observed in all 16 cases of CCC and of 
high amplitude (100-fold in average). miR-141 levels 
were not systematically down-regulated in 
chromophobe subtype, another subtype of renal cell 
carcinoma (Nakada et al., 2008). The exact mechanism 
that explain this down-regulation was not investigated 
but could be explained by copy number alterations 
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(losses) or the content of mesenchymal cells in the 
tumor samples compared to the normal kidneys. 
Gastric cancer 
Note 
Another cancer type where miR-141 was down-
regulated is gastric cancer. Thirty-five primary gastric 
cancer tissues were compared with pair-matched 
adjacent non-tumor tissues and the miR-141 was found 
significant lower in 80% of them (Du et al., 2009). 
Thyroid cancer 
Note 
Anaplastic thyroid carcinoma (ATC) is a highly 
aggressive type of thyroid carcinoma. In contrast to 
well-differentiated thyroid carcinomas, such as 
papillary (PTC) and follicular (FTC), the prognosis for 
ATC is very poor. Microarray analyses of miRNA 
abundance in three primary ATCs versus three normal 
thyroid samples identified miR-141, as well as other 
miR-200s, as down-regulated in ATCs (Braun et al., 
2010). Data in ATC cells indicate that miR-141 target 
TGFBR1 and SMAD2. Moreover, down-regulation of 
miR-141 distinguishes ATCs from other thyroid 
carcinomas, namely PTCs and FTCs. 
Esophageal cancer 
Note 
In order to explore the role of miRNAs on 
chemotherapy resistance, a study using nine human 
esophageal squamous cell carcinoma cell lines 
compared the miRNA profiles of cisplatin-resistant 
versus sensitive cell lines (Imanaka et al., 2011). miR-
141 was the most up-regulated miRNA in the resistant 
cell lines. It has been suggested that miR-141 confers 
resistance to cisplatin-induced apoptosis by targetin  
YAP1 (yes-associated protein), which induces 
apoptosis upon treatment with DNA-damage agents. 
Cancers 
Note 
In summary, levels of miR-200 family members, 
including miR-141 were found misregulated in several 
different types of cancer. These miRNAs are potential 
biomarkers of various cancers and could be used in 
non-invasive diagnosis and monitoring of the disease. 
Accordingly, there are several patents published in the 
field. 
Interestingly, miR-200 miRNAs were found up-
regulated in ovarian cancer, superficial bladder tumors 
and in the blood of ovarian, colorectal and prostate 
patients, but down-regulated in kidney (CCC) and 
invasive gastric cancer as well as in the urine of bladder 
cancer patients. 
The role of miR-200s in regulation of EMT process ha  
been demonstrated, but some questions about its role in 
metastasis and tumor progression still need to be 
elucidated. Since high expression of miR-200s is 
associated with an epithelial phenotype, one can 
hypothesize that miR-200 expression varies in the 
different steps of tumorigenesis. One can speculate th t 
miR-200 levels are high in primary tumors, become 
low during metastatic processes, when cells acquire 
mesenchymal characteristics, and could again be up-
regulated in the metastases, if they exhibit a more 
epithelial phenotype. In agreement with this theory, in a 
study that compared 43 primary tumors (colon, bladder, 
breast and lung) to their matched lymph node 
metastases, miR-141, as well as other miR-200s, was 
found down-regulated in metastatic cancers (Baffa et 
al., 2009). 
Besides their potential as diagnostic markers, miR-141 
and other miR-200s levels could also be indicative of 
response to chemotherapy, at least in ovarian and 
oesophageal cancers, as discussed before. 
Much remains to be done in the field to prove the rol  
of miR-141 in human cancers and its interest in clii s. 
Nevertheless, given the several studies already 
published, the miR-200 family will inevitably be 
considered in future developments of medical tools 





miR-200 family members, including miR-141 can 
regulate EMT by directly targeting ZEB1 and ZEB2 
factors, which are repressors of E-cadherin (CDH1). 
Conversely, ZEB1/2 factors can negatively regulate the 
transcription of these miRNAs, establishing a negative 
feedback loop (Bendoraite et al., 2010; Bracken et al., 
2008; Burk et al., 2008; Gregory et al., 2008; Korpal et 
al., 2008; Park et al., 2008). 
Stemness 
Note 
EMT being associated with stemness properties (Mani 
et al., 2008), miR-200 family has been involved in 
stemness by targeting ZEB1 (Wellner et al., 2009). 
Moreover, in both normal mammary stem cells and 
breast cancer stem cells, levels of miR-200 family 
miRNAs are reduced compared to non-tumorigenic 
cancer cells (Shimono et al., 2009). In addition to 
ZEB1 and ZEB2, miR-200 family members also target 
BMI1 and SUZ12, components of the PRC1 and PRC2 
Polycomb complexes, respectively (Iliopoulos et al., 
2010; Shimono et al., 2009), which are important for 
growth and function of cancer stem cells. 
Oxidative stress response 
Note 
miR-141 and other members of the miR-200 family are 
up-regulated following oxidative stress in different 
human and mouse cell lines (Magenta et al., 2011; 
Mateescu et al., 2011). Moreover, miR-141 and miR-
200a directly target the p38 (MAPK14) transcript, 
which is an important redox sensor (Mateescu et al., 
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2011). NRF2 pathway is a key cellular defense 
pathway against oxidative stress. These miRNAs, miR-
141/200a, also affect directly this pathway by targeting 
one of its key regulators, the NRF2 repressor, KEAP1 
(Eades et al., 2011; van Jaarsveld et al., 2012). 
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